

MaxCyte SPL Portfolio

August 6, 2025




 MaxCyte® e_xpert™ AT_x ST_x GT_x VL_x are registered trademarks of MaxCyte, Inc. in the U.S.A.

MaxCyte has an Active Portfolio of SPLs

Durable revenue is supported by 14 SPL clients with 18 active clinical programs, and 1 commercial program

18 Active Clinical Programs Represents ~\$210M of precommercial milestone potential¹



Cleared INDs or Equivalent

**Updated as of August 6, 2025*

- ✓ cGMP Compatible Platform
- ✓ FDA Master File and Technical Files
- ✓ Experienced FAS and sales support
- ✓ Leading know-how and engineering process improvement

SPL with active clinical trial →



1. Inclusive of ~\$10 million of milestones already received by MaxCyte

SPL Partners by Financing Stage


Private: Seed/Series A



Private: Series B/C



Public Company



Notable 2025 Financing:

- Beam Therapeutics: \$500M Public Financing March 2025
- Be Biopharma: Closed \$92M Series C Private Financing January 2025

Wound down



SPL with active clinical trial


SPL Portfolio: 22 Active Clinical Trials

Clinical Phase

- Phase 1
- Phase 1/2
- Pivotal
- Commercial

Cell Approach

- Allogeneic
- Autologous



As of August 2025 / Includes with SPL Programs with multiple Clinical Trials for different indications

Indications in Active MaxCyte-Enabled Clinical Trials

Genetic Diseases

Beta-Thalassemia
Sickle Cell Disease
Hemophilia B
Chronic Granulomatous Disease (CGD)

Solid Tumors

Non-small Cell Lung Cancer
Head and Neck Cancer
Glioblastoma
Renal Cell Carcinoma
Melanoma
Other Solid Tumors

Hematological Malignancies

Acute Lymphoblastic Leukemia
Acute Myeloid Leukemia
Chronic Lymphocytic Leukemia
Multiple Myeloma
Non-Hodgkin Lymphoma
T Cell Lymphoma

Autoimmune Disease


Lupus Nephritis
ANCA-associated Vasculitis
Multiple Sclerosis
Type 1 Diabetes
Other autoimmune diseases

Expanding Opportunity: Growth in Therapeutic Areas and Clinical SPL Programs

SPL Trials Across Multiple Therapeutic Areas

Therapeutic Area	Clinical/Commercial	Pre-Clinical
Genetic Disease	4	3
Blood Cancer	8	1
Solid Tumor	5	13
Autoimmune Disease	5	1
Neurodegenerative Disease	0	1
Total	22	19

SPL Programs (Clinical & Commercial) and Licensed Partners (SPL) Nearly Double in Last 5 Years







MaxCyte Supports the Future of Cell & Gene Therapies

WAVE 1	WAVE 2	WAVE 3	WAVE 4
1 Approved Product	5 Product Candidates	13 Product Candidates	19 Product Candidates
Vertex/ CRISPR CASGEVY®	Launch Potential: 2027 – 2028	Launch Potential: 2028 +	Launch Potential: 2032 +
Approved 2023 US FDA, European Commission & Additional Regulatory Bodies	5 products set to enter pivotal studies in next 6 to 18 months	13 products currently in Phase 1	19 products in preclinical development

MaxCyte's supports a diverse portfolio of product candidates with significant development milestone and commercial royalty potential

Source: Evaluate Pharma, Broker Estimates and MaxCyte Internal Estimates as of August 2025

Second Wave Set to Enter Pivotal Studies in Next 6 to 18 Months

SPL	Clinical Programs	Phase	Cell Type	Cell Approach	Indication
	CTX112	1/2	T-cells	Allogeneic	B-cell Malignancies
	WU-CART-007	1/2	T-cells	Allogeneic	Hematologic Malignancies
	Azer-Cel	1/1b	T-Cells	Allogeneic	Hematologic Malignancies
	CB010	1	T-Cells	Allogeneic	Hematologic Malignancies
Undisclosed	<i>Undisclosed Program</i>	1/2	<i>Undisclosed</i>	<i>Undisclosed</i>	<i>Undisclosed</i>

Illustrative Revenue Profile for a Successful SPL Program

Revenue Growth Drivers: Significant development milestones and high-value participation in future commercial success of partners' programs


Assumptions: First Approval in Year 7 | Approval in Three Geographic Regions
\$1.0B Peak Sales | Peak Sales Commercial Year 7 | Royalty 1.0%

● GTx Annual License Fee: \$0.25M/yr. (per GTx)

● Development/Regulatory Milestone: ~\$12M

● Royalty Payments in Aggregate: ~\$79M

+ Increasing PA Sales Through Clinical Development and Commercialization



Thank you!

Any questions?

ir@maxcyte.com



©2025 MaxCyte, Inc. All rights reserved. For a complete list of MaxCyte trademarks in the United States and other countries, please visit **maxcyte.com/trademarks**.

All other trademarks are the property of their respective owners.